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INTRODUCTION
Androgen receptor (AR) is an allosterically regulated transcription factor that binds to both the endogenous steroids testosterone and 5α-dihydrotestosterone and to a range of synthetic ligands. AR is central to prostate cancer pathogenesis and its reactivation is a hallmark of castrationresistant prostate cancer (CRPC), an aggressive and terminal illness for which there is no effective treatment. Despite this disease progression, most androgen-refractory prostate cancers continue to rely on AR for their survival; thus it remains an important therapeutic target. 1 Historically, approaches to modulate AR have focused on targeting the ligand-binding pocket with small molecules that sculpt the surface of the receptor in unique ways. 2 This indirect remodeling of the receptor binding surface results in the recruitment of different native binding partners. Although a powerful strategy, it has already been found that mutation of either binding surface (i.e. AR or cofactor) can occur, leading to, for example, antagonists that later become agonists. Epigenetic reader strategy to enhance AR function. Bi-functional recruiters contain a high affinity bromodomain inhibitor to recruit Brd4 to AR regulated promoters. One functional consequence of this mode of targeted recruitment could be up-regulation, as depicted. However, transcriptional inhibition may be observed due to steric blockade at some genes. 
BODY

Summary of Task 1 goals:
The primary focus of Task 1 was the design and synthesis of bi-functional molecules consisting of high-affinity AR ligands linked to class-selective HDACi. Full in vitro characterization of the bi-functional molecules comprises this Task. Molecules that demonstrated affinity for both targets comparable to unmodified inhibitors (within 2-to 4-fold) were carried on to Task 2.
Accomplishments of Task 1, Months 13-24:
As outlined in the Year One progress report, all goals of Task 1 were accomplished in the first twelve months of the Project with the exception of the synthesis of PD106 conjugates of andarine. This was completed and assessment of those molecules carried out in Task 2. A manuscript including preliminary results from Task 1 was recently accepted for publication and can be found in Appendix I (Jonas W. Højfeldt, Osvaldo Cruz-Rodríguez, Yasuhiro Imaeda, Aaron R. Van Dyke, James P. Carolan, Anna K. Mapp and Jorge A. Iñiguez-Lluhi, Molecular Endocrinology 2013 accepted for publication).
Summary of Task 2 goals:
Bifunctional molecules developed in the previous task will be examined in different cell lines (PC-3, LNCaP, VCaP) for their ability to modulate exogenous (luciferase) and endogenous (PSA, ERG) AR-driven reporters. Control experiments will also be performed to compare the effects of bifunctional molecules and HDACi alone (i.e. HDACi without an AR-targeting moiety).
(Months 4-18)
. Bifunctional recruiters that demonstrate cellular activity will be further examined as outlined in Task 3. If bi-functional molecules do not show efficacy in these assays, replacement of the HDACi recruitment moiety with an alternative inhibitor of chromatin modifying activities will be examined.
Accomplishments of Task 2, Months 13-24
Three-hybrid assay to assess recruitment by bi-functional molecules The data from Task 1 established that the bi-functional ligand design attenuated the affinity of each component ligand to its respective targets by only 2-5-fold. In this set of experiments, the goal was to assess if this would translate to recruitment of both targets to a promoter through a three-hybrid assay. In this experimental setup, a fusion of the HDAC of interest (HDAC3 is shown) to VP16 is expressed in the cells. As shown in Figure 2 , if the bi-functional molecule interacts with AR and with HDAC3 then the potent VP16 activation domain should lead to transcriptional activation of a luciferase reporter gene or an endogenous gene. In this assay the the HDAC of interest is fused to the potent transcriptional activator VP16; as an example, an HDAC3-VP16 construct is illustrated. Thus, if the bifunctional molecule interacts with both AR and the targeted HDAC at the promoter, then transcriptional up-regulation will be observed.
Andarine-O5-PD106 and hAR ± VP16-HDAC3
HEK293T cells were transfected with plasmids encoding full-length androgen receptor (1 µg), a luciferase reporter containing the prostate specific antigen promoter (1 µg), a fusion protein of HDAC3 with the VP16 TAD at its N-terminus and a FLAG tag at the C-terminus (1 µg), and a CMV driven β-galactosidase reporter (40 ng) using Lipofectamine 2000 (10 µL) in Opti-MEM media. Additionally, a second aliquot of cells were transfected using the same cocktail replacing HDAC3 with pBSSK+ as a negative control. The cells were allowed to recover overnight following transfection and were then trypsinized and plated on a 96 well plate (20,000 cells per well). After adhering for eight hours, cells were dosed with various concentrations of Andarine, Andarine-O5-N 3 , Andarine-O5-PD106, or DMSO as a vehicle control for eighteen hours. The cells were then lysed and the luciferase and β-galactosidase activity were assayed. Activation of the PSA reporter plasmid was normalized using β-galactosidase activity and is reported as fold activation over DMSO.
The moderate activation of the reporter plasmid by andarine is consistent with data reported in the literature and confirms that the cells were effectively transfected. 14 Andarine-O5-PD106 is also capable of activating the reporter to a moderate extent, though only at high concentrations and without any dependence on the presence of the VP16 fusion. Thus, the activation observed for the bifunctional molecule is not the result of dimerization of the target proteins, but instead is likely due to the inherent attenuated activation potential of the andarine component of the molecule.
Andarine-O5-PD106 and hAR + HDAC1-VP16
HEK293T cells were transfected as described above with the exception that the plasmid encoding the HDAC3 fusion protein was replaced with a plasmid encoding an HDAC1 fusion protein with the VP16 TAD at its C-terminus. The cells were allowed to recover and dosed as described above before luciferase and β-galactosidase activity were assayed. [Ligand] (µM) Fold Activation over DMSO PD106 is a slow, tight-binding Class I (HDAC1, HDAC2, HDAC3, and HDAC8) selective HDAC inhibitor. 15 After the observation that Andarine-O5-PD106 could not dimerize AR and HDAC3, the experiment was repeated using an alternative Class I HDAC, HDAC1. Dosing with andarine again resulted in moderate activation of the reporter, confirming the cells were effectively transfected. Consistent with the results using VP16-HDAC3, the bifunctional molecule failed to dimerize the target proteins and the observed activation at high concentrations of the conjugate is again likely due to the inherent activation potential of the andarine component of the molecule.
RU486-O3/O5-SAHA and hAR ± VP16-HDAC3
After the disappointing results of the previous experiments we hypothesized that the use of an antiandrogen as the AR targeting agent would lead to an AR form that would be more easily controlled extrinsically. Towards that end, we designed and synthesized two bifuunctional molecules composed of the antiantrogen RU486 conjugated to the pan-specific HDAC inhibitor SAHA through a polyethylene glycol linker. 7, 16 Two molecules containing different linker lengths were prepared and assessed to determine the impact of linker length on the activity of the molecules. HEK293T cells were transfected as described for the previously described VP16-HDAC3 three-hybrid experiment. Following the transfection, cells were allowed to recover and were then dosed with various concentrations of RU486-O3-SAHA, RU486-O5-SAHA, RU486-O3-N 3 , andarine, or DMSO as a vehicle control for eighteen hours before luciferase and β-galactosidase activity were assayed. Consistent with previous experiments, andarine led to moderate activation of the reporter, confirming the effective transfection of the cells. Dosing with RU486-O3-N 3 led to very low activation (~1-4 fold over DMSO), consistent with the function of the parent molecule as a partial agonist antiandrogen. 16 The two conjugates tested led to significant activation at high concentrations of small molecule, with no apparent dependence on linker length. Interestingly, this activation is also not dependent upon the presence of the VP16 containing HDAC3 fusion protein. These data suggest that the conjugate is not dimerizing the target proteins with the desired effect, as transcription is significantly potentiated rather than abrogated even in the absence of the VP16 fusion protein.
Several reports suggest that treatment with low concentrations of SAHA can lead to enhanced transcriptional output in exogenous reporter systems. [17] [18] [19] The loss of transcriptional activity at high doses of the trans addition (> 5 µM; data not shown) is consistent with the reported IC 50 values for SAHA in cellular proliferation assays against several prostate cancer cell lines. 20 Thus, the activity of the bifunctional molecule is explained by the activities of the individual component molecules, RU486 and SAHA. Furthermore, the conjugate displays lower potency and efficacy than the addition of the molecules in trans, which is likely a result of the diminished binding affinity of the proteins for the molecules due to the modifications made in order to link them.
Re-design of bi-functional molecule Our data from Task 1 and results from our model system (Appendix 1) illustrate the fundamental feasibility of extrinsic control of androgen receptor function through bifunctional recruiters. The primary difficulty with the HDACi-based molecules appears to be ineffective recruitment at the promoter level. Thus we sought to replace the HDACi moiety with an alternative recruiter and target epigenetic reader proteins (i.e. bromodomains) instead of epigenetic erasers (i.e. HDACs). (S)-JQ1 is a highly potent and selective inhibitor of bromodomain 4 (BRD4) which is known to intereact with critical components of the transcriptional machinery (e.g. CDK9, cyclin T1, RNA Pol II). Because our bifunctional molecules are constructed modularly, it is straightforward to conjugate existing advanced intermediates with JQ1 using our synthetic strategies developed for Task 1
RU-O3-JQ1
RU-O3
RU-O8-JQ1
Functional assessment of JQ1-based agents In contrast to the AR three hybrid system used to assess the HDACi-based conjugates, to test these constructs we have targeted full length human glucocorticoid receptor (hGR) as we and others have observed a more robust dynamic range in the transcriptional response. The schematic for his assay is shown below in Figure 6 . We examined a range of promoters regulated by GR to test the effect of promoter architecture on recruitment and functional outcome. Although one would expect the primary response of Brd4 recruitment to be transcriptional up-regulation, in some cases steric effects may lead to repression. Figure 6 . Functional assay for testing JQ1-based bifunctional molecules. In this assay, bifunctional molecules are tested for there ability to localize endogenous human glucocorticoid receptor (hGR) to a reporter vector and upregulated the transcription of luciferase. Upstream of the luciferase gene is a glucocorticoid response element (GRE) sequence for hGR binding based on a consensus GRE or a GRE found in an endogenous, hGR-regulated gene. In this assay format, bifunctional molecule recruitment of BRD4 yields higher levels of activation relative to a glucocorticoid antagonist in both a dose-dependent and time-dependent manner.
Shown in Figure 7 are the results of examining four distinct GR-regulated promoters. Briefly, U2-OS cells were seeded in a six-well plate and transfected with a blank pCDNA3 vector (750 ng) along with plasmids encoding full length human glucocorticoid receptor (250 ng), β-galactosidase (500 ng), and firefly luciferase (500 ng) using Lipofectamine 2000 (5 uL) in serum-less media. A consensus glucocorticoid response element (GRE) or GRE based on a glucocorticoid receptor gene was cloned upstream of the luciferase expression gene. Following overnight recovery, cells were trypsinized and replated in charcoalstripped media in a 96-well plate at a seeding density of 5,000 cells per well. After adhering for six hours, cells were dosed with RU-O3-N3, RU-O3-JQ1, or DMSO as a vehicle control for eighteen hours, or the specified time. The cells were then lysed and assayed for luciferase or β-galactosidase activity. Luciferase activity was normalized to β-galactosidase activity and is reported as fold activation over DMSO. As expected, the pattern of transcriptional response varied significantly with promoter architecture. The FKBP and Pal promoters, for example, exhibited a robust response relative to RU-486 bearing only the linker. Although not shown explicitly in these graphs, trans addition did not produce these effects, indicating that the physical linkage between RU-486 and JQ1 is a requirement. Additionally, a construct bearing the enantiomer of JQ1, a molecule that cannot bind to Brd4, has no activity in these assays. Finally, increasing the linker length between JQ1 and RU-486 did not lead to enhanced activity. Thus, we continue to focus on the RU-O3-JQ1 conjugate. In addition to the dose-response observed in the data of Figure 7 , we observed a time-dependence ( Figure  8 ). In the case of the consensus GRE and GILZ promoters, for example, significant additional activity was observed after 8 hours.
Consensus GRE-luc Taken together, these exciting data indicate that bifunctional recruiters that target epigenetic readers such as JQ1 have robust in a full length nuclear receptor. These molecules will also serve as ligands for AR so we are well-poised to test this in our prostate cancer model system.
Assessment and future milestones for Task 2:
As outlined in the Task 2 summary our current efforts are focused on functional characterization of the bifunctional molecules based upon the JQ1 scaffold. This will be accomplished through the examination of endogenous AR-regulated genes (PSA, ERG for example) in addition to luciferase assays. In addition to the RU486 molecules, we will examine andarine-based and bicalutamide-based constructs synthesized and evaluated as previously outlined. The best molecules will be carried on to Task 3.
Summary of Task 3 goals
The goals of Task 3 as originally articulated focused on assessing the changes in acetylation pattern, cell growth and apoptosis stimulated by the HDACi-based inhibitors; in other words, these experiments were designed to test the endogenous functional consequences of treating cells with the HDACi-based bifunctional molecules. Although the design of the bifunctional molecules has been modified to incorporate bromodomain inhibitors such as JQ1, the new experimental goals remain aligned: we will examine both cell growth and apoptosis in LnCAP cells upon treatment with the RU486-JQ1 conjugates. Additionally, as andarine and bicalutamide conjugates emerge from the Task 2 experiments, they will similarly be assessed. Further, we will characterize the most promising molecules by genomewide expression analysis. These latter experiments are particularly important as they will enable assessment of which genes are up-regulated by Brd4 recruitment, which are repressed and how this varies based upon the identity of the AR ligand. These experiments are the top priority for the third year of funding as they will be the most informative for selecting molecules for Task 4 assessment.
KEY RESEARCH ACCOMPLISHMENTS
• Evaluated first and second generation suite of HDACi-based bifunctional models in cellular models of AR function in an extensive suite of experiments. These data established that while dual targeting is feasible in cell-free environments, in the context of full-length receptor at endogenous genes, intrinsic pathways dominate.
• Optimal linker identity and length was identified and validated in a model study for both binding and function. These results were accepted for publication (see Appendix 1)
• A re-design of the bifunctional molecules targeted the epigenetic reader Brd4 as the recruitment moiety. The previously designed synthetic strategy enabled rapid preparation and assessment of this scaffold.
• The JQ1-based conjugates can be used, for the first time, to extrinsically regulate the function of a fulllength receptor at endogenous promoters. This is a critical step forward.
REPORTABLE OUTCOMES
• A model study that enabled identification of key elements of a functioning bifunctional transcriptional regulator has been accepted for publication (see Appendix 1)
• The Task 
CONCLUSIONS
The overall goal of this research project is to develop and implement a conceptually innovative strategy for down-regulating androgen receptor: the creation of bifunctional molecules that simultaneously bind to the androgen receptor and to chromatin modifying complexes. In this way, AR function can be extrinsically controlled. In this second year of funding, we made critical progress towards this goal with the demonstration that targeting an epigenetic reader, Brd4, is a successful strategy. In addition, the workflow is well established such that additional molecules are being streamlined through the process. In the next funding period, the focus will be on full functional characterization of the molecules in more advanced prostate cancer model systems.
M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Abstract: Therapies based on conventional nuclear receptor ligands are extremely powerful yet their broad and long term use is often hindered by undesired side effects which are often part of the receptor's biological function. Selective control of nuclear receptors such as the glucocorticoid receptor using conventional ligands has proven particularly challenging. Because they act solely in an allosteric manner, conventional ligands are constrained to act via cofactors that can intrinsically partner with the receptor. Furthermore, effective means to rationally encode a bias for specific coregulators are generally lacking. Using the glucocorticoid receptor as a framework, we demonstrate here a versatile approach based on bifunctional ligands that extends the regulatory repertoire of the glucocorticoid receptor in a deliberate and controlled manner. By linking the macrolide FK506 to a conventional agonist (Dexamethasone) or antagonist (RU-486), we demonstrate that it is possible to bridge the intact receptor to either positively or negatively acting coregulatory proteins bearing an FK506 binding protein domain. Using this strategy, we show that extrinsic recruitment of a strong activation function can enhance the efficacy of the full agonist dexamethasone and reverse the antagonist character of RU-486 at an endogenous locus. Notably, extrinsic recruitment of HDAC1 reduces the ability of GR to activate transcription from a canonical GR response element while preserving ligand-mediated repression of NFkB. By providing novel ways for the receptor to engage specific coregulators, this unique ligand design approach has the potential to yield both novel tools for GR study and more selective therapeutics. are an important element of immunosuppressive regimens for organ transplantation (1) . Despite thesewell-established and sometimes life-saving therapeutic applications, conventional glucocorticoid therapy 1 is severely limited due to undesirable side effects. These are mainly due to the profound metabolic 2 changes in energy and protein metabolism that endogenous glucocorticoids set in motion as an adaptive 3 response to transient stress. Consequently, pharmacologic glucocorticoid excess leads to hyperglycemia, 4 visceral adiposity, and insulin resistance as well as muscle wasting and osteoporosis. Pharmacologic 5 approaches that mitigate the metabolic effects of glucocorticoids while preserving their 6 immunomodulatory activity would be a major therapeutic advance. This however, has proven elusive 7 despite intense efforts (2-4). 8
The effects of glucocorticoids are mediated by the glucocorticoid receptor (GR) a prototypic member 9 of the nuclear receptor superfamily of sequence-specific ligand regulated transcription factors. Upon 10 binding of an agonist to the C terminal ligand binding domain (LBD), GR translocates to the nucleus and 11 localizes to specific loci through a central zinc finger region capable of direct recognition of specific 12 sequences or through tethering to other transcription factors. From these sites, GR influences the 13 transcription of target genes by nucleating the assembly of specific coregulatory complexes through 14 protein-protein interactions (5). The receptor orchestrates this process by integrating multiple signals (6), 15 including variations in the target DNA sequence (7), intracellular signaling cascades, post-translational 16 modifications (8, 9) and uniquely, small cell-permeable ligands that bind to the LBD (Fig.1A) . The difficulties associated with conventional NR ligands are likely to be due in large part to the fact 8 that they act solely through allosteric modulation of receptor conformation and are therefore constrained 9 to recruit from a closed set of cofactors that are within the intrinsic interaction envelope of the receptor. 10
This puts a limit to the range of achievable functional effects. Furthermore, despite the incorporation of 11 novel protein dynamics criteria (13), it is not yet possible to rationally design into a conventional ligand 12 the ability to recruit specific coregulator complexes or to generate a particular pattern of gene expression. 13 A further challenge is that coactivators involved in transactivation such as GRIP1 also participate in 14 transcriptional repression mechanisms (14, 15) . Furthermore, the development of clinical resistance is a 15 significant problem, particularly in cancer therapy (16) . 16 In a significant departure, we describe here a novel strategy that circumvents the limitations of 17 conventional allosteric ligands and frees the receptor to engage in novel extrinsic functional interactions 18 that are open to rational design. The approach leverages the versatility of GR bifunctional ligands which 19 although have proven useful in three hybrid assays (17) , have never been exploited to regulate the intact 20 GR in its native context. By linking prototypic agonist and antagonist GR ligands to the small molecule 21 FK506, we have thus generated bifunctional ligands that can bind the intact receptor and bridge it to 22 designed transcriptional activators or corepressors containing the FK506 binding protein (FKBP) domain 23 (Fig.1B) . Using this strategy, we demonstrate for the first time that the regulatory repertoire of the native 24 receptor at endogenous genomic loci can be expanded by directing the deliberate recruitment of extrinsiccoregulators. This strategy allows the designed reprogramming of the intact receptor and can 1 dramatically enhance or completely reverse the efficacy of conventional ligands. By eliciting unique 2 responses, this new class of GR ligands can thus serve as mechanistic probes to discern which are the 3 relevant "on pathway" transcriptional responses required for specific therapeutic effects and which are not 4 required or causative of undesired side effects (18) 
Materials and Methods
9
Synthesis and binding affinity of GR bifunctional ligands 10
The macrolide FK506 was installed via a polyethylene glycol linker to a Dexamethasone (Dex) 11 derivative where the 21-hydroxyl group is replaced by a thioether linkage (19) . For the RU486 12 derivatives, a similar linker strategy was employed using the aniline group of RU486 as the attachment vectors for WT rat GR and β-galactosidase respectively. pGBR 6.1 is a luciferase based reporter 10 harboring a 500 bp intronic region of the human FKBP5 gene and has been described previously (11, 22) . 11
The 5× NFκB Luciferase reporter (23) was a kind gift of Dr. Gabriel Nuñez, (University of Michigan). 
Results
20
Design of bifunctional ligands 21
Using the glucocorticoid receptor as a paradigm and building on the significant experience in 22 structure-activity relationship for GR ligand conjugates (17, 19, (25) (26) (27) (28) , we created bifunctional 23 molecules based on the agonist Dex and the antagonist RU486. The least perturbing derivative of Dexthat allows facile conjugation with other molecules has been termed SDex, in which the 21-hydroxyl 1 group is replaced by thioether linkages (19) (Fig. 2) . RU486 has been linked to bile acids through its 2 aniline group and retained antagonistic activity (28) . Using a polyethylene-glycol linker as a spacer, we 3 have thus conjugated these ligand derivatives to the natural product FK506 (Fig. 2) . Our choice was 4 based on the extensive experience using FK506 conjugates for ligand induced protein complex assembly 5 (29, 30) . Compounds bearing a linker only were synthesized as controls (Fig. 2) . 6
The binding affinity of the conjugates for full-length GR was determined in a radiolabeled Dex 7 competition binding assay. As can be seen in Fig. 3A , the affinities of SDex-O 3 -OMe and SDex-O 2 -8 FK506 are approximately 50 and 100 nM. Although this is 10 and 20 fold lower than the affinity of Dex 9 (5 nM), these values are in a range comparable to the affinity of endogenous steroids such as cortisol (20 10 nM). Although conjugation of FK506 to SDex, lowers the binding affinity a modest 2-fold, this 11 difference is not due to effects of binding cellular FK506-binding proteins since binding studies done in 12 the presence of free FK506 yielded similar results (not shown). In the case of the RU486 derivatives, 13 both compounds displayed comparable affinities (~90 nM), which are less than an order of magnitude 14 (~6-fold) lower than that of unmodified RU486 (Fig. 3B) . From this analysis, it is clear that the synthetic 15 strategy yielded bifunctional ligands that retain significantly high affinity for GR. 16
Extrinsic recruitment of a designed coactivator enhances GR ligand efficacy 17
FK506-binding proteins such as human FKBP1A bind with sub-nanomolar affinity to FK506 and the 18 fact that this high-affinity interaction is retained even when the macrolide is conjugated to other 19 molecules has made this pairing the basis for multiple successful small-molecule mediated protein 20 recruitment strategies (31) . As a first approach, we designed and constructed a coactivator fusion protein 21 consisting of a nuclear localization signal, the strong transcriptional activation domain of the herpes 22 simplex virion protein 16 (VP16), and FKBP1A and examined its ability to modulate GR activity by 23 monitoring the transcriptional output of a GR-stimulated reporter driven by a natural GR enhancersequence. As can be seen in Fig. 4A , in the absence of any fusion protein, the Dex-derived bifunctional 1 molecules (SDex-O 2 -FK506 and SDex-O 3 -OMe) led to a dose-dependent enhancement of activity with 2 both compounds achieving maximal responses comparable to that of the parent agonist Dex. As expected 3 from their somewhat reduced binding affinity, these compounds activated with lower potency relative to 4
Dex. Interestingly, even though SDex-O 2 -FK506 has discernably lower affinity than SDex-O 3 -OMe, both 5 compounds activated with comparable potencies suggesting an advantage for the FK506 conjugate. From 6 this data, it is apparent that despite the presence of the linker and FK506 moiety, the bifunctional ligands 7 remain cell permeable and retain full efficacy revealing a significant degree of steric tolerance by the 8 native receptor. 9
In notable contrast, in the presence of the VP16-FKBP fusion (Fig. 4B) , the FK506-conjugated ligand 10 (SDex-O 2 -FK506) displayed a nearly two fold increase in maximal activity relative to Dex and the 11 corresponding EC 50 of 0.76 nM reflects a ~7 fold increase in potency relative to the linker only ligand 12 (SDex-O 3 -OMe). Notably, these effects were specific to the FK506 conjugated ligand since the presence 13 of the fusion did not appreciably alter the response to Dex or SDex-O 3 -OMe. Thus, the enhancement 14 depends on both the fusion and the FK506 moiety of the ligand. These data argue that the enhanced 15 activation in the presence of the fusion is due to extrinsic recruitment by the bifunctional ligand. If this is 16 indeed the case, it can be anticipated that the effect should be disrupted by excess unconjugated FK506 17 (32) . In support of this prediction, increasing concentrations of free FK506 reduced the activity of the 18 bifunctional ligand (Fig. 4C) Therapeutically, GR ligands that have reduced transactivation efficacy but retain full agonism in 5 repression contexts have been sought after since they may display more favorable efficacy vs. side effect 6 profiles. Since these properties have proven to be difficult to obtain using conventional ligands, we 7 sought to build upon our initial results and use the extrinsic control approach to explicitly design and 8 implement this desired regulatory outcome. Since recruitment of corepressor complexes is a common 9 strategy employed by transcription factors to negatively regulate transcription, we constructed a designed 10 coregulator where FKBP1A is fused to the histone deacetylase HDAC1, an enzyme which is an integral 11 component of multiple corepressor complexes (33, 34) . In the presence of this coregulator, we then 12 examined the ability of SDex based bifunctional ligands to mediate GR activity in both a canonical 13 activation context (as examined in the experiments above, Fig. 5A left) as well as in a repression context 14 (Fig.5A right) where GR inhibits TNFα-stimulated NFκB activity. As in the case of pro-inflammatory 15 cytokine genes, GR is recruited to DNA indirectly by tethering to NFκB and inhibits transcription in an 16 agonist-dependent manner, likely at a step downstream of RNA pol II recruitment (35, 36) . As can be 17 seen in Fig. 5B left, in the presence of the FKBP-HDAC1 coregulator, the maximal response elicited at 18 the activation context by SDex-O 2 -FK506 was significantly blunted, reaching only ~30% of the response 19 induced by Dex. In contrast, the fusion did not alter the activity elicited by either Dex itself or SDex-O 3 -20 OMe (compare to Fig. 4) . These results indicate that extrinsic recruitment of HDAC1 can successfully 21 oppose the intrinsic efficacy of a conventional ligand in an activation context. In notable contrast, 22
analysis of the tethering repression context (Fig 5B, right) revealed that both the control and FK506 23 conjugated SDex bifunctional ligands supported GR-mediated inhibition of NFκB to the same extent as 24 Dex (Fig. 5B) . Since this same repression activity profile was observed in the absence of any fusionprotein (data not shown), this indicates that the FKBP-HDAC1 coregulator did not interfere with the 1 ability of the ligands to repress in this context. As expected given their lower intrinsic affinity, the 2 bifunctional ligands were less potent than Dex in both the activation and repression contexts. Taken 3 together, the results indicate the successful establishment of the desired outcome and underscore the 4 deliberate design potential of the extrinsic recruitment approach. 5
Efficacy switch from antagonist to agonist through extrinsic recruitment 6
The above experiments show that in an activation context, it is possible to positively or negatively 7 modulate the efficacy of an agonist ligand by the judicious extrinsic recruitment of coregulators. To 8 probe the design versatility and scope of this approach, we sought to determine to what extent the 9 regulatory effects of extrinsically recruited factors can be dissociated from the efficacy intrinsic to the GR 10 binding moiety of the bifunctional ligand. To this end, we examined the properties of RU486 based 11 ligands where the receptor binding moiety is an antagonist. As can be seen in the left panels of Fig. 6, in  12 the absence of any fusion, RU486 and its derivatives showed no detectable activation of the GR 13 responsive promoter (Fig. 6A, left) . The compounds, however, are active and cell permeable since they 14 are able to antagonize the activity of 3 nM Dex in a dose-dependent manner (Fig. 6B, left) . Interestingly, 15 even though both RU486 based ligands have indistinguishable affinities (Fig. 3B) In contrast to the above data, in the presence of the VP16-FKBP fusion, RU486-O 3 -FK506 became an 21 effective inducer of transcriptional activation reaching a maximal activity nearly as strong as that of Dex 22 ( Fig. 6A, right) . Interestingly, the response is biphasic since activation is reduced at the highest 23 concentration. This behavior however, is consistent with the properties of bifunctional ligands, since atsufficiently high concentrations, formation of binary ligand-protein complexes is favored over the ternary 1 one (32, 37) . It is also notable that half-maximal activation by the FK506 conjugate occurred at 2 concentrations (EC 50 ~3nM) significantly lower than the intrinsic receptor affinity (~90 nM). 3
Importantly, and similarly to the case of the Dex derivatives, the activity depends on both the fusion 4 protein and the FK506 moiety and can be disrupted with free FK506 (Fig. 6A and not shown) . 5 Consistent with a large gain in efficacy, the behavior of the ligands in the presence of 3nM Dex (Fig.  6 6B right) indicated that RU486-O 3 -FK506 behaved as an agonist and increased activity beyond 3 nM 7
Dex. The fact that the peak activity is higher than that observed with RU486-O 3 -FK506 alone also 8 suggests that at these concentrations, where mixed occupancy is likely, cooperation between intrinsic 9 (Dex bound GR) and extrinsic (RU486-O 3 -FK506 bound GR) mechanisms is occurring. As anticipated 10 from competitive displacement, the behavior at the highest concentrations is comparable to that of 11 RU486-O 3 -FK506 alone. Furthermore, the presence of the VP16-FKBP fusion did not appreciably alter 12 the antagonistic behavior of the parental RU486 or the conjugate lacking FK506 indicating that the 13 observed effects require both the appropriate coregulator and the FK506 moiety in the bifunctional ligand. 14 Taken together, these data clearly show that the regulatory effects elicited through extrinsic recruitment 15 can be fully dissociated from the intrinsic properties of the GR binding moiety. The versatility of the 16 approach is such that it allows for the predictable reprogramming of the transcriptional output of GR such 17 that the behavior of a ligand can be completely reversed from an antagonist to an agonist. 18
Regulation in an intact chromatin environment through extrinsic recruitment 19
The implementation of the overall GR transcriptional program in vivo occurs in the context of a 20 complex chromatin environment and any successful ligand strategy must be able to operate under these 21 circumstances. To demonstrate that GR-extrinsic transcriptional control can also be achieved at 22 endogenous GR target genes in their native chromatin context, we focused on the S100P gene. The basal 23 expression of this gene in HEK293T cells is comparatively low and can be stimulated ~50 to 100 fold byDex only upon GR expression. These properties indicate that the receptor is a major determinant of 1 S100P transcription and make it a suitable target for analysis. In cells co-expressing FKBP alone, both of 2 the SDex derivatives at 100 nM (which is comparable to their dissociation constant) were able to activate 3 the S100P gene ~ 20 fold (Fig. 7A, left) . In contrast, in cells co-expressing the VP16-FKBP fusion, 4 S100P expression was three fold higher in the presence of SDex-O 2 -FK506 compared to the control 5 ligand SDex-O 3 -OMe, which lacks the FK506 moiety (Fig.7A center) . In fact, the activity elicited by the 6 FK506 conjugate reached levels comparable to those obtained with the same concentration of Dex (which 7 in comparison, corresponds to a 20 fold excess over its own dissociation constant). On the other hand, in 8 cells expressing the HDAC1-FKBP fusion, S100P expression in response to SDex-O 2 -FK506 was 9 reduced by half in comparison to SDex-O 3 -OMe (Fig.7A, right) . Thus, for both the positive and negative 10 modulation, successful extrinsic control can be demonstrated in a manner that depends on both the 11 appropriate coregulator partner as well as on the FK506 moiety in the ligand. A parallel analysis of the 12 effects of the RU486 based ligands (Fig.7B) revealed that in the presence of FKBP alone, the ligands did 13 not appreciably activate S100P expression. This is expected from the intrinsic antagonist nature of 14 RU486. In the presence of the VP16-FKBP fusion however, the FK506 conjugate successfully activated 15 S100P expression more than 10 fold compared to the ligand lacking the FK506 moiety. Importantly, 16 western blot analysis demonstrated successful expression of the fusion proteins (Fig. 7C, bottom) and 17 comparable expression of the receptor (Fig. 7C, top) . Taken together, the data clearly indicate that the 18 extrinsic recruitment approach can be readily used to reprogram the expression of genes in their natural 19 context and thus is amenable to further development for potential therapeutic applications. 20
Discussion
21
The ligand design we have implemented demonstrates that it is possible to independently manipulate 22 intrinsic as well as extrinsic pathways of GR control and that their combinatorial coupling via 23 bifunctional ligands can yield a variety of regulatory outcomes in both activation and repression contexts 24 (Table 1 ). The approach is instructive in multiple ways since it reveals mechanistic features of GRfunction and opens up numerous design opportunities for its directed manipulation. The ability of the 1 intact GR LBD to accommodate both agonist and antagonist based bifunctional ligands is notable since 2 the predicted exit trajectory of the linker from the LBD based on structural information is quite different. 3
For the Dex derivatives, the linker attachment site is very close to the surface and projects outward 4 between helix 3 and 11 on the opposite side of helix 12. The linker is likely accommodated with minor 5 movements of nearby residues such as T739 and Ile 747. The ability of the bifunctional ligands on their 6 own to mount maximal responses comparable to Dex argues that the linker is accommodated while 7 preserving a functional AF2. For the RU406 derivatives, the linker extends from the aniline moiety, 8 which is responsible for preventing helix 12 from adopting an active conformation and is already solvent 9 exposed. Despite opposite exit points from the LBD and a relatively short linker, both bifunctional 10 ligands are proficient for the recruitment of designed coregulators, which indicates a significant degree of 11 flexibility and steric tolerance. These properties are favorable to the further development of the extrinsic 12 recruitment approach. 13
The ability of the HDAC1-FKBP coregulator to limit transactivation by GR is also revealing. On the 14 one hand, the inhibitory effect does not appear to be due to steric hindrance because FKBP alone or 15 fusions to other proteins of comparable size are inactive (not shown). Furthermore, although our data is 16 consistent with the established role of HDAC1 as a component of corepressor complexes, recent data 17 based on the functional effects of HDAC1 knockdown has been interpreted as HDAC1 playing a positive 18 role in GR transactivation (38) . Whether this reflects indirect effects of HDAC1, or more complex 19 interactions as has been suggested recently (39), remains to be determined. It is also important to note 20 that HDACs can play key scaffolding roles in corepressor complexes that do not depend on their HDAC 21 activity (34, 40) . Consistent with this view, initial data indicates that the catalytic activity of HDAC1 is 22 not required for its ability to suppress GR transactivation in the extrinsic recruitment approach (not 23 shown). . This would indicate that the catalytic site of HDAC1 could be targeted by bifunctional ligands 24 to recruit functional corepressor complexes. Importantly, targeting HDAC1 allowed selective reductionof GR transactivation while preserving agonist mediated repression. Such an outcome is difficult to 1 obtain with conventional ligands because the same AF-2 directed coregulators, such as GRIP1 can 2 participate in both contexts (15) . 3
The ligand design we have implemented has unique properties that make it amenable to directed 4 design strategies. The nearly independent manipulation of the properties of both the receptor binding 5 moiety and the additional chemical functionality is a significant advantage. This modularity extends the 6 receptor's own design where the DNA and ligand specificity have divergently evolved to generate distinct 7 receptors with unique properties and functions. The substantial level of flexibility afforded by this 8 approach greatly increases the types of ligands that can be envisioned. Although we have demonstrated a 9 controlled change in efficacy with prototypic agonist and antagonist receptor ligands, the strategy could 10 be combined with compounds with some conventional dissociated properties (2) or the arylpyrazole 11 nonsteroidal series (3) that display some cell and gene selective properties to leverage both intrinsic and 12 extrinsic effects. The experiments described here demonstrate that the added functionality afforded by 13 the bifunctional ligand can be used in explicit design efforts to direct a desired transcriptional output and 14 override the intrinsic properties of the receptor binding moiety. This also means that ligands with very 15 high affinity but with weak efficacy could be used as scaffolds. Such a strategy could counteract the mild 16 penalty in affinity incurred by the introduction of the linker. 17
It is also important to note that in addition to affecting the pharmacodynamic properties of a receptor 18 ligand, the linker as well as the additional chemical functionality in the bifunctional ligand can influence 19 its pharmacokinetics and this can be advantageous. Thus, studies of an analogous Dex conjugate series 20 indicate that the thiourea linker used here confers favorable properties both for cellular permeability (44) 21 and trans-scleral transport in the context of ocular delivery (45) . Our data also indicates that the FK506 22 moiety enhances the cellular potency of Dex (Fig. 4) as well as RU486 based bifunctional ligands (Fig. 6)  23 relative to their intrinsic receptor affinities (Fig. 3) , an effect observed even in the absence of designed 24 FKBP fusion proteins (Fig 6B, left) . The enhanced potency may be a reflection of increased cellularuptake or retention provided by the FK506 group, particularly since FK506 can serve as a substrate and 1 inhibitor of drug efflux transporters such as MDR1 (41) . Notably, the favorable pharmacokinetic 2 properties provided by FK506 have been recently demonstrated for drug conjugates both in vitro and in 3 vivo (42, 43) . Similarly, conjugation of GR antagonists to bile acids has been explored as a means to 4 target GR antagonism to the liver (28) . The oral bioavailability, tissue distribution and microsomal 5 stability of such conjugates (28) indicate that GR bifunctional ligands can have pharmacokinetic 6
properties suitable for further clinical development. 7
The experiments presented here depend on genetic manipulation of the designed coregulator. 8
Although this may be incorporated as part of gene-therapy strategies, transition to bifunctional ligands 9 acting on purely endogenous proteins will obviously depend on appropriate functionalities that can target 10 coregulator complexes. In this regard, the recent progress by our group (46) (47) (48) and others (49) in the 11 development of small molecules that can mimic activation domains offer some clear opportunities (50) . 12
Enhancing the agonist efficacy of glucocorticoid ligands in this manner could provide a means to 13 overcome or alleviate steroid resistance, which is an important clinical problem in diseases such as 14 asthma (51, 52), nephrotic syndrome (53) and malignancies such as acute lymphoblastic leukemia (54) . 15 Similarly, such ligands could restore function to carriers of mutations in GR that impair interaction with 16 coactivators (55, 56) . Indeed, the modular design of our bifunctional ligands argues for the successful 17 incorporation of these chemical motifs to target endogenous regulatory complexes. 18
Bifunctional ligands made as FK506 conjugates as in this study have intriguing prospects in their own 19 right as mechanistic tools. They can be used to directly recruit specific FKBP-coactivator or corepressor 20
fusions. This can provide a means to not only identify factors that can overcome gene-specific rate-21 limiting barriers to activation or to provide novel mechanisms of repression for specific GR target genes. 22
For example, extrinsic recruitment of factors implicated in GR mediated repression at tethering sites such 23 as NELF (14) could enhance the repressive effects of agonists in a gene selective manner. By examining 24 multiple cofactors in parallel, this approach could also be used to establish epistatic relationships betweenthem and the gene subsets affected by them. It is precisely this type of knowledge that is required to 1 identify the most desirable regulatory profile for a given therapeutic application. Furthermore, the 2 approach could also be used to establish or monitor specific epigenetic marks at GR targeted loci in a 3 ligand dependent manner as has been recently illustrated for Oct4 (57) . Clearly, the strategy outlined here 4 has significant potential and opens the possibility of instructive ligand design not only for GR but for the 5 entire nuclear receptor class. 6 Table   Table 1 these complexes to AR regulated promoters will lead to the downregulation of genes required for prostate cancer cell survival. Bifunctional molecules capable of binding both AR and HDAC complexes present an attractive approach to implementing this strategy and are currently being investigated.
To this end, a potent AR ligand has been synthesized, to which a polyethylene glycol linker has been appended. Early biological characterization using chromatin immunoprecipitation has demonstrated the ability of the modified ligand to effectively localize and bind AR to DNA. Additionally, an HDAC inhibitor is currently being investigated for potential use within the proposed strategy.
